Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.

Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R.

Value Health. 2011 Jul-Aug;14(5):652-6. doi: 10.1016/j.jval.2011.01.006. Epub 2011 Jun 2.

2.

Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.

Villacorta R, Hay JW, Messali A.

Pharmacoeconomics. 2013 Sep;31(9):823-39. doi: 10.1007/s40273-013-0078-x.

PMID:
23975739
3.

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.

Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B.

J Dermatolog Treat. 2011 Jun;22(3):138-43. doi: 10.3109/09546634.2010.542800. Epub 2011 Jan 22.

PMID:
21254886
4.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

5.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

6.

Ustekinumab for the treatment of moderate to severe psoriasis.

Gospodarevskaya E, Picot J, Cooper K, Loveman E, Takeda A.

Health Technol Assess. 2009 Oct;13 Suppl 3:61-6. doi: 10.3310/hta13suppl3/10. Review.

PMID:
19846031
7.

Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.

Ferrándiz C, García A, Blasco AJ, Lázaro P.

J Eur Acad Dermatol Venereol. 2012 Jun;26(6):768-77. doi: 10.1111/j.1468-3083.2011.04357.x. Epub 2011 Nov 30.

PMID:
22126264
8.

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A; ACCEPT Study Group.

N Engl J Med. 2010 Jan 14;362(2):118-28. doi: 10.1056/NEJMoa0810652.

9.

Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting.

Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M.

Appl Health Econ Health Policy. 2012 Sep 1;10(5):343-53. doi: 10.2165/11633980-000000000-00000.

PMID:
22877226
10.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

11.

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

Uhlenhake EE, Feldman SR.

Expert Opin Biol Ther. 2010 Jul;10(7):1105-12. doi: 10.1517/14712598.2010.487061. Review.

PMID:
20446825
12.

Cost-effectiveness of psoriasis therapy with etanercept in Germany.

Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke WH.

J Dtsch Dermatol Ges. 2007 Sep;5(9):762-8. English, German.

PMID:
17760896
13.

Comparing biological therapies in psoriasis: implications for clinical practice.

Griffiths CE.

J Eur Acad Dermatol Venereol. 2010 Oct;24 Suppl 6:10-4. doi: 10.1111/j.1468-3083.2010.03831.x.

PMID:
20831704
14.

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.

Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, Guzzo C, Li S, Hsu MC, Strober B.

J Am Acad Dermatol. 2012 May;66(5):731-41. doi: 10.1016/j.jaad.2011.06.011. Epub 2011 Sep 17.

PMID:
21930328
15.

Infliximab for the treatment of adults with psoriasis.

Loveman E, Turner D, Hartwell D, Cooper K, Clegg A.

Health Technol Assess. 2009 Jun;13 Suppl 1:55-60. doi: 10.3310/hta13suppl1/09.

16.

Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis.

Schmitt-Rau K, Rosenbach T, Radtke MA, Augustin M.

Dermatology. 2010;221(3):236-42. doi: 10.1159/000320111.

PMID:
20924159
17.

Biological treatments for moderate-to-severe psoriasis: indirect comparison.

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.

J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

PMID:
23442134
18.

Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.

[No authors listed]

Prescrire Int. 2009 Oct;18(103):202-4.

PMID:
19882785
19.

Economic evaluation of etanercept in the management of chronic plaque psoriasis.

Lloyd A, Reeves P, Conway P, Reynolds A, Baxter G.

Br J Dermatol. 2009 Feb;160(2):380-6. doi: 10.1111/j.1365-2133.2008.08863.x. Epub 2008 Sep 19.

PMID:
18808413
20.

Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system.

de Portu S, Del Giglio M, Altomare G, Arcangeli F, Berardesca E, Calzavara-Pinton P, Lotti T, Martini P, Peserico A, Simonacci M, Vena GA, Girolomoni G.

Dermatol Ther. 2010 Jan-Feb;23 Suppl 1:S7-13. doi: 10.1111/j.1529-8019.2009.01280.x. Erratum in: Dermatol Ther. 2010 Jul-Aug;23(4):434. Pinton, Piergiacomo Calzavara [corrected to Calzavara-Pinton, Piergiacomo].

PMID:
20136921

Supplemental Content

Support Center